Details of the Drug

General Information of Drug (ID: DMBI4JG)

Drug Name

Isosorbide dinitrate

Synonyms

Angidil; Astridine; BiDil; Cardis; Carvanil; Carvasin; Cedocard; Claodical; Cornilat; Coronex; Corosorbide; Corovliss; Difutrat; Dignionitrat; Dilatrate; Diniket; Dinitroisosorbide; Dinitrosorbide; Disorlon; Emoper; EureCor; Flindix; Frandol; Harrical; ISD; ISDN; IsoBid; Isochron; Isodinit; Isoket; Isorbid; Isordil; Isostat; Isotrate; Korodil; Langoran; Laserdil; Lomilan; Maycor; Myorexon; Nitrosorbid; Nitrosorbide; Nitrosorbon; Nosim; Resoidan; Rigedal; Sorbangil; Sorbide; Sorbidilat; Sorbidinitrate; Sorbidnitrate; Sorbislo; Sorbitrate; Sorbonit; Sorquad; Sorquat; Tinidil; Titradose; Vascardin; Vasodilat; Vasorbate; Xanyl; Cedocard Retard; Dilatrate SR; Dinitrato de isosorbida; Iso Bid; Isomak R; Isordil Tembids; Isosorbide dinitrato; Isosorbide dinitrato [DCIT]; Isosorbidi dinitras; Isosorbidi nitras; Rifloc Retard; Sorbide nitrate; Sorbidi nitras; Cardio 10; Cardonit 40; IBD 20; Isoket Retard 120; Isoket Retard120; Isoket retard 40; TYB 3215; Cedocard (TN); D-Isosorbide dinitrate; Dilatrate-SR; Dinitrate d'isosorbide; Dinitrate, Isosorbide; Dinitrato de isosorbida [INN-Spanish]; Iso-Bid; Iso-Mack; Iso-Puren; Isoket Retard-120; Isordil (TN); Isosorbidi dinitras [INN-Latin]; SDM No. 40; SDM No. 50; SST-101; Sorate-10; Sorate-5; Sorbide, dinitrate; Sorbitrate (TN); D-Isosorbide dinitrate-Lactose mixture; Dianhydrosorbitol 2,5-dinitrate; Dilatrate-sr (TN); Dinitrate d'isosorbide [INN-French]; Isosorbide 2,5-dinitrate; Sorbide T.D.; Glucitol, 1,4:3; Isosorbide dinitrate (JP15/USP/INN); Isosorbide dinitrate [USAN:INN:BAN:JAN]; Isosorbide dinitrate mixture with not <60% lactose, mannose, starch or calcium hydrogen phosphate [UN2907] [Flammable solid]; D-Glucitol, 1,4:3,6-dianhydro-, dinitrate; D-Glucitol, 1,4:3,6-dianhydro-, 2,5-dinitrate; [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate; 1,4:3, 6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydro-D-glucitol dinitrate; 1,4:3,6-Dianhydrosorbitol 2, 5-dinitrate; 1,4:3,6-Dianhydrosorbitol 2,5-dinitrate; 1,4:3,6-dianhydro-2,5-di-O-nitro-D-glucitol

Indication

Disease Entry	ICD 11	Status	REF
Anal fissure	DB50.0	Approved	[1], [2]
Angina pectoris	BA40	Approved	[1], [2]

Therapeutic Class

Vasodilator Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

236.14

Topological Polar Surface Area (xlogp)

1.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 31 mL/min/kg [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 7.2596 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.72% [4]
Vd: The volume of distribution (Vd) of drug is 2-4 L/kg [7]
Water Solubility: The ability of drug to dissolve in water is measured as 1.089 mg/mL [3]

Chemical Identifiers

Formula: C6H8N2O8
IUPAC Name: [(3S,3aS,6R,6aS)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
Canonical SMILES: C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]
InChI: InChI=1S/C6H8N2O8/c9-7(10)15-3-1-13-6-4(16-8(11)12)2-14-5(3)6/h3-6H,1-2H2/t3-,4+,5-,6-/m1/s1
InChIKey: MOYKHGMNXAOIAT-JGWLITMVSA-N

Cross-matching ID

PubChem CID: 6883
ChEBI ID: CHEBI:6061
CAS Number: 87-33-2
DrugBank ID: DB00883
TTD ID: D0I1SK
INTEDE ID: DR0888
ACDINA ID: D00333

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylate cyclase (GC)	TT6HPVC	NOUNIPROTAC	Stimulator	[8], [9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Glutathione S-transferase alpha-1 (GSTA1)	DE4ZHS1	GSTA1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Isosorbide dinitrate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Cariprazine.	Bipolar disorder [6A60]	[34]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Selegiline.	Depression [6A70-6A7Z]	[35]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Isocarboxazid.	Depression [6A70-6A7Z]	[35]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and OPC-34712.	Depression [6A70-6A7Z]	[34]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Procarbazine.	Hodgkin lymphoma [2B30]	[35]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Captopril.	Hypertension [BA00-BA04]	[36]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and ITI-007.	Insomnia [7A00-7A0Z]	[34]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Ozanimod.	Multiple sclerosis [8A40]	[35]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Promethazine.	Nausea/vomiting [MD90]	[34]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Safinamide.	Parkinsonism [8A00]	[35]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Rasagiline.	Parkinsonism [8A00]	[35]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Levomepromazine.	Psychotic disorder [6A20-6A25]	[34]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Quetiapine.	Schizophrenia [6A20]	[34]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Mesoridazine.	Schizophrenia [6A20]	[34]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Aripiprazole.	Schizophrenia [6A20]	[34]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Iloperidone.	Schizophrenia [6A20]	[34]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Paliperidone.	Schizophrenia [6A20]	[34]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Molindone.	Schizophrenia [6A20]	[34]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Thiothixene.	Schizophrenia [6A20]	[34]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Amisulpride.	Schizophrenia [6A20]	[34]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Asenapine.	Schizophrenia [6A20]	[34]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[34]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Isosorbide dinitrate and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[37]
-----------


⏷ Show the Full List of 23 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Dibasic ammonium phosphate	E00305	44134541	Buffering agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Isosorbide dinitrate 20 mg tablet	20 mg	Oral Tablet	Oral
Isosorbide dinitrate 40 mg tablet	40 mg	Oral Tablet	Oral
Isosorbide dinitrate 2.5 mg tablet	2.5 mg	Sublingual Tablet	Oral
Isosorbide dinitrate 40 mg tablet	40 mg	Extended Release Oral Tablet	Oral
Isosorbide dinitrate 40 mg capsule	40 mg	Extended Release Oral Capsule	Oral
Isosorbide dinitrate 10 mg tablet	10 mg	Oral Tablet	Oral
Isosorbide dinitrate 5 mg tablet	5 mg	Oral Tablet	Oral
Isosorbide dinitrate 5 mg tablet	5 mg	Sublingual Tablet	Oral
Isosorbide dinitrate 30 mg tablet	30 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7051).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040009.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
9	No recovery of cold complex regional pain syndrome after transdermal isosorbide dinitrate: a small controlled trial. J Pain Symptom Manage. 2009 Sep;38(3):401-8.
10	Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett. 1999 Jun 11;452(3):165-9.
11	Nitroglycerin and isosorbide dinitrate stimulation of glutathione disulfide efflux from perfused rat liver. Biochem Pharmacol. 1989 Nov 1;38(21):3807-10.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55.
22	Human glutathione transferase A3-3, a highly efficient catalyst of double-bond isomerization in the biosynthetic pathway of steroid hormones. J Biol Chem. 2001 Aug 31;276(35):33061-5.
23	Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6.
24	Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C. 1987;88(1):91-3.
25	Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23.
26	In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs. 2006 Jan;24(1):3-14.
27	Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7.
28	Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5.
29	Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7.
30	Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther. 2000 Apr;67(4):432-7.
31	Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82.
32	Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12.
33	Clinical pipeline report, company report or official report of Cyclerion Therapeutics.
34	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
35	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
36	Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7. [PMID: 1901528]
37	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.